Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Bartsch, R.; Harbeck, N.; Wrobel, D. et al.
Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinibBREAST. Bd. 68. 2023 S. S20-S21
Schmidt, Mona W.; Fan, Carolyn; Koeppinger, Karl F. et al.
Laparoscopic but not open surgical skills can be transferred to robot-assisted surgery: A systematic review and meta-analysisWORLD JOURNAL OF SURGERY. 2023
Battista, Marco Johannes; Anic, Katharina; Linz, Valerie et al.
Long term safety data of epidural anesthesia in elderly patients with ovarian cancer-results of a retrospective cohort studyZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE. Bd. 56. 2023 S. S2-S3
Decker, Thomas; Ludtke-Heckenkamp, Kerstin; Melnichuk, Luidmila et al.
Maintenance Therapy with ET and Ribociclib after 1st line Chemotherapy (CT) in Hormone Receptor (HR)-positive/HER2-negative Metastatic Breast Cancer (BC): a Phase II Trial (AMICA)CANCER RESEARCH. Bd. 83. H. 5. 2023
Weide, R.; Feiten, S.; Wassmann, C. et al.
Metastatic breast cancer: survival improvement in routine care 1995-2022ONCOLOGY RESEARCH AND TREATMENT. Bd. 46. 2023 S. 28-28
Harbeck, Nadia; Wrobel, Denise; Zaiss, Matthias et al.
Neratinib as extended adjuvant treatment of HER2-positive/HR-positive early breast cancer patients in Germany, Austria and Switzerland: interim results of the prospective, observational ELEANOR studyBREAST CARE. 2023
Janni, Wolfgang; Fehm, Tanja; Muller, Volkmar et al.
Omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer - interim results from the randomized phase 3 DETECT V trialCANCER RESEARCH. Bd. 83. H. 5. 2023
Hasenburg, Annette; Blohmer, Jens-Uwe; Janni, Wolfgang et al.
Oncology - Dose-intensive training in gynecological oncology - AGO State of the Art 2023GEBURTSHILFE UND FRAUENHEILKUNDE. Bd. 83. H. 10. 2023 S. 1179-1183
Pfisterer, Jacobus; Joly, Florence; Kristensen, Gunnar et al.
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III TrialJOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 4. 2023 S. 893-+
Kreipe, Hans; Schmidt, M
Pathologie, Prognose und PrädiktionUntch, Harbeck, Thomssen, Lüftner (Hrsg). Colloquium Senologie. München: Lukon 2023